Zachary Schug, Ph.D.

Zachary Schug, Ph.D.

Laboratory

The Schug Laboratory

Contact

215-898-3705
zschug@wistar.org

https://twitter.com/SchugLab

Assistant Professor, Molecular & Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center

About the Scientist

Schug is interested in investigating metabolic adaptation in cancer cells through the use of cell biology, biochemistry, liquid chromatography-mass spectrometry (LC-MS)-based lipidomics and metabolomics. 

After completing his B.S. in biology from Saint Joseph’s University, Schug continued his studies in Philadelphia and earned a Ph.D. in molecular cell biology from Thomas Jefferson University. In 2008, he began his postdoctoral studies at the Beatson Institute in Glasgow, U.K. Schug joined The Wistar Institute in 2016 as an assistant professor. He also holds adjunct faculty positions in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania and the Department of Biochemistry and Molecular Biology at Drexel University.

View Publications

The Schug Laboratory

Alterations in the acquisition and metabolism of nutrients are now firmly recognized as hallmarks of cancer development. Many, if not all, oncogenes and tumor suppressor genes induce metabolic reprogramming in cancer cells through changes in the regulation of enzymes and transporters. These changes are necessary for cancer cells to meet the combined biomass and energy demands for growth and are only satisfied by increased capture and synthesis of cellular building blocks such as sugars, fats, and proteins. In addition, cancer cells often invade other tissues where the availability of certain nutrients is drastically different or grow so quickly that the blood supply, and the accessibility to oxygen and other nutrients that comes with it, becomes scarce. During these conditions of nutrient stress, many cancer cells will adapt and use alternative available resources to survive.

The Schug laboratory is interested in identifying and therapeutically targeting the metabolic changes that arise during the development of cancer and metastasis. They combine cell biology, biochemistry, metabolomics, lipidomics and genomics to uncover novel metabolic vulnerabilities in cancer. These targets are then further developed for use as effective therapeutic strategies for the improved treatment of cancer patients.

Staff

Postdoctoral Fellow

Dzmitry Mukha, Ph.D.

Research Assistants

Seamus O’Connor
Katherine Pniewski

Graduate Students

Joshua Shaffer
Sabina Hlavaty
Kelsey Salcido

Undergraduate Student

J. Tanner Nelson

ALUMNI

Postdoctoral Fellow

Katelyn Miller, Ph.D., former postdoc and American Cancer Society fellow (2017-2021); Research Scientist, Janssen Pharmaceuticals

Michael Hulse, Ph.D., former postdoc (2019-2020); Research Scientist, Prelude Therapeutics

Jessica Casciano, Ph.D., former postdoc (2016-2018); Licensing officer at Penn Center for Innovation.

Undergraduate Students

Sara Papp, Undergraduate research student (2018-2020); Medical school student at UT Southwestern Medical School

Aaron Anil, Wistar Biomedical Technician Training Program (2021)

Aurora Dalipaj, Wistar Biomedical Technician Training Program (2018); Dental school student at the University of Pennsylvania School of Dental Medicine.

Jessie Velasco, UPenn Summer Undergraduate Intern (2017); Ph.D. student in Biochemistry Department at University of Utah.

Jorgji Ndrecka, Wistar High School Summer Fellow (2016); Undergraduate student in University of the Sciences Philadelphia.

Julia Kurylec, Summer Undergraduate Intern (2019); Continuing undergraduate degree at Temple University.

Adam Cohen-Nowak, Wistar Institute (2016-2018); Medical Student at Thomas Jefferson University Medical College.

Available Positions

Motivated candidates are encouraged to inquire about the positions below. Contact zschug@wistar.org.

Postdoctoral Fellow
Selected Publications

Stine, Z.E., Schug, Z.T., Salvino, J.M., Dang, C.V. “Targeting Cancer Metabolism in the Era of Precision Oncology.” Nat Rev Drug Discov. 2022 Feb;21(2):141-162. doi: 10.1038/s41573-021-00339-6.

Miller, K.D.,  Pniewski, K. , Perry, C.E., Papp, S.B., Shaffer, J.D., Velasco-Silva, J.N., Casciano, J.C., Aramburu, T.M., Srikanth, Y.V.V., Cassel, J., et al. “Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth.” Cancer Res. 2021 Mar 1;81(5):1252-1264. doi: 10.1158/0008-5472.CAN-20-1847. Epub 2021 Jan 7.
 

Casciano, J.C., Perry, C., Cohen-Nowak, A.J., Miller, K.D., Vande Voorde, J., Zhang, Q., Chalmers, S., Sandison, M.E., Liu, Q., Hedley, A., et al. “MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.” Br J Cancer. 2020 Jan 16. doi: 10.1038/s41416-019-0711-3.

Schug, Z.T., Voorde, J.V., Gottlieb, E. “The Metabolic Fate of Acetate in Cancer.” Nat Rev Cancer. 2016 Nov;16(11):708-717. doi: 10.1038/nrc.2016.87. Epub 2016 Aug 26.
 

Schug, Z.T., Peck, B., Jones, D.T., Zhang, Q., Grosskurth, S., Alam, I.S., Goodwin, L.M., Smethurst, E., Mason, S., Blyth, K., et al. “Acetyl-CoA Synthetase 2 Promotes Acetate Utilization And Maintains Cancer Cell Growth Under Metabolic Stress.” Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002.

View Additional Publications